drugset / Trial / NCT02805179

A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

NCT02805179 ↗

Phase 2 Completed 26 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This is a study to determine the safety and effectiveness of high-dose radiation therapy (RT) with concurrent temozolomide in patients with newly diagnosed glioblastoma.

Timeline

Start
2016-09-22
Primary completion
2020-02-06
Completion
2020-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 75 mg/m2 —
Subject Temozolomide Small molecule 150 mg/m2 —
Subject Temozolomide Small molecule 200 mg/m2 —

Indications